Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017
This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy with intravenous administration of cetuximab and avelumab followed by avelumab maintenance therapy in patients with locally advanced head and neck cancer, unfit for cisplatin.
Epistemonikos ID: 519a50345a7865525a4deb825c8b3d7a4099b582
First added on: May 17, 2024